Try Seraph 100

EU

Seraph 100 as seen on 60 Minutes

Military Programs Aiming to End Pandemics Forever

Watch Now

Revolutionary

COVID-19 Pathogen Adsorption Therapy

ExThera Medical’s Seraph® 100 Microbind® Affinity Blood Filter is a revolutionary hemoperfusion medical device that addresses unmet clinical needs in treating bloodstream infections and reducing pathogens. Learn how clinicians are using the Seraph 100 to treat COVID-19.
Learn More

Seraph 100 Microbind Affinity Blood Filter Technology

The Seraph 100 uses microbead adsorption media with chemically-bonded heparin to mimic the binding sites that pathogens use when they invade the body. Selectively adsorbed pathogens remain bound in the filter.

Learn More

How Seraph 100 is Saving Lives

Extracorporeal—meaning outside the body—blood purification treatments are usually reserved for the severely or critically ill. Learn more about the role of Seraph 100 in treating COVID-19.

Learn More

In the News

See what’s happening at ExThera Medical and recent updates about the Seraph 100.

All News

ExThera Medical Corporation
757 Arnold Drive, Suite B
Martinez, California 94553
p: (925) 839-2060 | f: (925) 839-2075
e: info@extheramedical.com

Seraph 100 News
Providers Investors
Patients About
DISCLAIMERS
*The Seraph® 100 Microbind® Affinity Blood Filter (Seraph) is CE Marked and approved for commercial sale in EU member states.
**Emergency Use Authorization Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100) is for use in the United States under FDA EUA200165:
Authorization for Emergency Use in patients with COVID-19 admitted to the ICU with confirmed or imminent respiratory failure.
The Seraph 100 device has neither been cleared or approved for the indication to treat patients with COVID-19 infection.
The Seraph 100 device has been authorized by FDA under an Emergency Use Authorization (EUA).
The Seraph 100 device is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of the Seraph device 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.